Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
MedPage Today on MSN
First Drug for Deadly Transplant Complication Gets FDA's Blessing
The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...
Gov. Newsom declared a state of emergency in several Californian counties due to severe weather risks, such as flooding and ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
The human complement system has a pivotal role in the recognition, opsonization and elimination of microbial intruders. This functionality is maintained by a well-balanced interaction network of serum ...
YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...
Riedemann, Chief Executive Officer and Founder of InflaRx , commented: “InflaRx welcomes the granting of izicopan as the INN for INF904. We believe the promising clinical data recently reported in ...
Recent research from the Medical University of South Carolina laboratory of Russell Norris, Ph.D., challenges the notion that ...
Reporting on ASH 2025, Dr Jamile Shammo highlights long-term follow-up data for established paroxysmal nocturnal ...
A devastating fire at Gombe's Kasuwar Katako Timber Market destroyed goods worth N600m, leaving over 60 traders facing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback